Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Puja Sapra

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Molecular Cancer Therapeutics|October 27, 2011
Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancerYixian Zhang, Stephen Castaneda, Melissa Dumble, et al.
Molecular Cancer Therapeutics|December 11, 2012
Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cellsPuja Sapra, Marc Damelin, John Dijoseph, et al.
Bioconjugate Chemistry|July 15, 2016
Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) PayloadsSujiet Puthenveetil, Frank Loganzo, Haiyin He, et al.
Molecular Therapy. Oncology|April 10, 2024
Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12Cheyne Kurokawa, Sonia Agrawal, Abhisek Mitra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2020
Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid LeukemiaYoon-Chi Han, Jennifer Kahler, Nicole Piché-Nicholas, et al.
Cell Reports. Medicine|June 7, 2021
NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cellsKenneth G Geles, Yijie Gao, Andreas Giannakou, et al.
Molecular Cancer Therapeutics|July 6, 2022
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint BlockadeAndrea T Hooper, Kimberly Marquette, Chao-Pei Betty Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2015
Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor RegressionsMarc Damelin, Alexander Bankovich, Albert Park, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 21, 2014
A general approach to site-specific antibody drug conjugatesFeng Tian, Yingchun Lu, Anthony Manibusan, et al.
Molecular Cancer Therapeutics|August 5, 2020
PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung CancersEdmund I Graziani, Matthew Sung, Dangshe Ma, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Molecular Cancer Therapeutics|October 27, 2011
Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancerYixian Zhang, Stephen Castaneda, Melissa Dumble, et al.
Molecular Cancer Therapeutics|December 11, 2012
Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cellsPuja Sapra, Marc Damelin, John Dijoseph, et al.
Bioconjugate Chemistry|July 15, 2016
Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) PayloadsSujiet Puthenveetil, Frank Loganzo, Haiyin He, et al.
Molecular Therapy. Oncology|April 10, 2024
Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12Cheyne Kurokawa, Sonia Agrawal, Abhisek Mitra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2020
Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid LeukemiaYoon-Chi Han, Jennifer Kahler, Nicole Piché-Nicholas, et al.
Cell Reports. Medicine|June 7, 2021
NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cellsKenneth G Geles, Yijie Gao, Andreas Giannakou, et al.
Molecular Cancer Therapeutics|July 6, 2022
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint BlockadeAndrea T Hooper, Kimberly Marquette, Chao-Pei Betty Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2015
Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor RegressionsMarc Damelin, Alexander Bankovich, Albert Park, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 21, 2014
A general approach to site-specific antibody drug conjugatesFeng Tian, Yingchun Lu, Anthony Manibusan, et al.
Molecular Cancer Therapeutics|August 5, 2020
PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung CancersEdmund I Graziani, Matthew Sung, Dangshe Ma, et al.
Pageof 6